Digene: study confirms HPV testing more sensitive than conventional, liquid-based Pap test

By Lisa Kerner

Charlotte, N.C., June 7 - Digene Corp. said a study using its Hybrid Capture 2 High-Risk HPV DNA Test found that testing for high-risk types of the human papillomavirus (HPV) is a significantly more sensitive tool for cervical cancer screening than either conventional (by 40%) or liquid-based cytology (Pap testing) (by 30%).

The study of more than 33,000 women was funded in part by the European Union and the Italian Ministry of Health and published in the June issue of the Journal of the National Cancer Institute.

"This is a milestone study in that it is the first randomized, controlled study to compare HPV DNA testing to both conventional and liquid-based cytology," chief scientific officer Attila T. Lorincz said in a company news release.

"It strongly reinforces results from earlier, smaller screening studies showing that the use of HPV testing as part of cervical cancer screening significantly increases our confidence that no woman at risk of malignancy will go undetected."

Located in Gaithersburg, Md., Digene develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.